Evidence map›Paper›PMID 41368010›Full record

ReviewThe Lancet regional health. Western Pacific2025

Drug-resistant gram-negative bacterial infections in children in the Oceania region: review of the epidemiology, antimicrobial availability, treatment, clinical trial and pharmacokinetic data, and key evidence gaps.

Daniel K Yeoh, Alison Boast, Sophie Ch Wen, Phoebe Cm Williams, Lesley Voss, Brett Ritchie, Mona Mostaghim, Flora Lutui, Alice Lei, Tony Lai and 8 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet regional health. Western Pacific, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Daniel K YeohDepartment of Infectious Diseases, Perth Children's Hospital, Perth, Australia.
Alison BoastAntimicrobials Group, Murdoch Children's Research Institute, The Royal Children's Hospital Melbourne, Parkville, Australia.
Sophie Ch WenInfection Management Prevention Service, Children's Health Queensland, Brisbane, Australia.
Phoebe Cm WilliamsDepartment of Infectious Diseases, Sydney Children's Hospitals Network, Sydney, Australia.
Lesley VossDepartment of Paediatric Infectious Diseases, Starship Children's Hospital, Auckland, New Zealand.
Brett RitchieInfectious Diseases Department, Women's and Children's Hospital, North Adelaide, Australia.
Mona MostaghimDepartment of Pharmacy, Sydney Children's Hospital, Sydney, Australia.
Flora LutuiDepartment of Paediatrics, Vaiola Hospital, Nukualofa, Tonga.
Alice LeiAntimicrobials Group, Murdoch Children's Research Institute, The Royal Children's Hospital Melbourne, Parkville, Australia.
Tony LaiSydney Institute for Infectious Diseases, School of Public Health, Faculty of Medicine The University of Sydney, Sydney, Australia.
Adam D IrwinInfection Management Prevention Service, Children's Health Queensland, Brisbane, Australia.
Kiera HarwoodAntimicrobials Group, Murdoch Children's Research Institute, The Royal Children's Hospital Melbourne, Parkville, Australia.
Thomas EwinDepartment of Pharmacy, Royal Darwin Hospital, Darwin, Australia.
Celia CooperInfectious Diseases Department, Women's and Children's Hospital, North Adelaide, Australia.
Emma BestDepartment of Paediatric Infectious Diseases, Starship Children's Hospital, Auckland, New Zealand.
Sarah BannisterAntimicrobials Group, Murdoch Children's Research Institute, The Royal Children's Hospital Melbourne, Parkville, Australia.
Amanda GweeAntimicrobials Group, Murdoch Children's Research Institute, The Royal Children's Hospital Melbourne, Parkville, Australia.
KIDS DOSE group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gram-negative bacterial infections remain a major cause of morbidity and mortality in children and neonates globally, compounded by the rise of antimicrobial resistance. Barriers to paediatric antibiotic licencing lead to reduced availability of potentially effective agents for treatment. For children and neonates in the Oceania region, specific challenges remain including a paucity of surveillance data on local rates of antimicrobial resistance, and lack of availability of newer, more costly agents. In this review, we summarise available regional epidemiological data on the WHO priority pathogens: extended spectrum B-lactamase (ESBL)-producing Enterobacterales, carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant

Indexed as

Carbapenem-resistantChildrenDrug-resistantESBLGram-negativePaediatric

Identifiers

PMID41368010
PMCPMC12685515

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.